Introduction
The global medical device-grade conductive adhesive market is undergoing an interesting transformation.
According to market research data, this segment accounts for approximately 12% of the overall conductive adhesive market, with a compound annual growth rate expected to remain above 6% through 2028. The core drivers behind this growth are not traditional medical consumables, but three emerging application scenarios: wearable health monitoring devices, patient monitoring equipment, and implantable devices.
Meanwhile, industry surveys show that approximately 68% of medical device manufacturers rank “adhesive performance improvement” as a key consideration in next-generation product development—not “important,” but “key.”
The market is expanding, choices are increasing, but the most common mistake companies make in selection remains: making the decision the moment they flip to the parameter table.
Reason #1: A Overlooked Detail Behind Market Data—”Batch-to-Batch Consistency” Is Not Listed on Parameter Tables
Behind the 6% growth rate lies a large number of new products entering clinical use. And every new product brought to clinical must answer the same question: Can I guarantee that every batch of adhesive performs exactly the same as the batch submitted for testing?
The supplier’s parameter table tells you the adhesive’s initial viscosity, tensile strength, curing time, and temperature resistance. But what it doesn’t tell you is:
- What is the formulation change control mechanism? When did the supplier last adjust the catalyst source—three years ago or three months ago? Did they notify you?
- Where is the multi-batch chemical consistency data? What is the acceptable variation range for photoinitiator residue levels between different batches?
- Has the supplier established a Raw Material Change Notification (PCN) mechanism? Did you include this clause in your procurement contract?
The parameter table is static, but the supply chain is dynamic. As the market expands, supplier capacity pressure also increases—expansion often comes with raw material source adjustments and process fine-tuning, and these adjustments may not be proactively communicated to every customer.
This is not suggesting suppliers intentionally hide information, but reminding that evaluating “supplier change control capability” during the selection phase is a matter worth clarifying early on.
Reason #2: Rapid Growth of Wearable Devices Has Redefined “Safety Boundaries”
The fastest-growing segment in the medical device adhesive market is not implants, but wearable devices.
Patient monitoring equipment currently represents the largest application area for conductive adhesives, followed by surgical instruments and implantable devices. The special of wearable devices lies not just in “sticking,” but in maintaining both adhesive and conductive performance under conditions of prolonged skin contact, continuous movement, and exposure to sweat.
The requirements for adhesives in this context can no longer be summarized as “meeting performance parameters”—what is required is comprehensive performance under actual use conditions over extended periods.
And this type of data cannot be covered by standard testing. Passing ISO 10993 biocompatibility testing under standard conditions does not guarantee that this adhesive will maintain performance when a marathon athlete wears it continuously for 48 hours in a dynamic sweating environment.
This is why more and more companies are introducing simulation-based use condition validation studies during the selection phase, rather than making decisions based solely on ISO 10993 reports.
Reason #3: Statistical of Market Reports and Regulatory Review Are Two Different Worlds
Industry reports use growth rates and market share to help you judge market trends, but regulatory review logic is completely different—they don’t look at market data, but at whether your specific product under specific use conditions has sufficient safety evidence.
The disconnect between these two worlds is reflected in a very practical issue:
Most adhesive performance data cited in market reports comes from testing under standard laboratory conditions. However, when FDA, NMPA, and EMA review combination products, they examine which compounds patients are actually exposed to under worst-case use conditions.
Market data helps you choose direction; E&L studies help you pass review. Both are necessary conditions, but they are not the same thing.
Selection Is Not About Checking Parameter Tables—It’s About Building Systematic Evaluation Capability
The common thread across these three reasons is: adhesive selection is a decision requiring systematic evaluation capability, not a process of comparing numbers on parameter tables.
A relatively complete selection evaluation framework should include at minimum:
- Formula verification—complete supplier formula (all additives with CAS numbers) + confirmation of change control mechanisms
- Process compatibility assessment—whether curing process parameters match your production conditions
- Sterilization process impact assessment—whether the supplier has chemical comparison data after gamma/EO/steam sterilization
- Use condition E&L studies—extractables and leachables studies under laboratory-simulated actual use conditions
- Toxicological risk assessment—safety argumentation based on measured data
No supplier’s parameter table can cover all of the above. Companies that build systematic selection capability are not comparing who chose a better adhesive, but who identified risks earlier.
What key factors should be evaluated beyond the parameter table during medical device adhesive selection?
Beyond basic performance parameters, evaluators should assess the supplier’s change control mechanisms, batch-to-batch consistency data, and whether they have established a Raw Material Change Notification (PCN) system. These factors determine whether the adhesive will maintain consistent performance across different production batches throughout the product lifecycle.
How do wearable device applications challenge traditional adhesive selection criteria?
Wearable devices require adhesives to maintain both adhesion and conductivity under prolonged skin contact, continuous movement, and sweat exposure. This goes beyond standard performance parameters and demands validation studies simulating actual use conditions—not just ISO 10993 biocompatibility testing under standard laboratory conditions.
Why is E&L (Extractables & Leachables) testing essential for regulatory approval?
While market data helps identify growth opportunities, regulatory bodies like FDA, NMPA, and EMA focus on whether your specific product under actual use conditions has sufficient safety evidence. E&L studies identify what compounds patients are exposed to, which is critical for passing regulatory review even when the adhesive performs well under standard tests.
What components should a comprehensive adhesive selection framework include?
A complete framework should cover: formula verification with complete additive information and CAS numbers, process compatibility assessment, sterilization impact evaluation, use condition E&L studies, and toxicological risk assessment. No single parameter table can provide all this information—systematic evaluation is key to identifying risks early.
Brunslab is a Chinese laboratory headquartered in Guangzhou, specializing in Extractables & Leachables (E&L) studies for pharmaceutical packaging and medical device materials. | Contact: Tel: +86 20 31068557 | Email: contact@brunslab.com
